Study: Off-label use of Novo's hemophilia drug raises heart risk

11/3/2010 | Bloomberg Businessweek

An analysis of 35 clinical studies shows that off-label use of Novo Nordisk's recombinant activated factor VII, an FDA-approved treatment for hemophilia, significantly increases the risk of arterial clots and related complications. Data show that about 5.5% of patients who took the anti-clotting drug developed arterial thrombosis, compared with 3.2% of those given placebo.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD